



Andrew Spencer

Contact

Andrew Spencer

Publications (4)

Sonneveld P, Dimopoulos M, Boccadoro M, Quach H, Ho P, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof I, van de Donk N, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hájek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen E, Vanquickenberghe V, Sitthi-Amorn A, Van de Velde C, Carson R, Rodriguez-Otero P, Bladé J, Moreau P, PERSEUS Trial Investigators. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. *N Engl J Med* 2023; 390:301-313.

Sonneveld P, Driessen C, Pour L, Levin M, Bos G, Ypma P, Wu K, van de Velden V, Oliva S, Broijl A, Croockewit A, Boccadoro M, Spencer A, Palumbo G, Offidani M, van de Donk N, Hveding C, Waage A, Minnema M, Troia R, Cornelisse P, Zamagni E, Zander T, Zweegman S, Ludwig H, Aquino S, van der Holt B, Beksac M, Dimopoulos M, Wester R, Hájek R, Gulbrandsen N, Gregersen H, Morelli A, De Rosa L, Cafro A, Gay F, Dozza L, Pantani L, Cavo M. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. *J Clin Oncol* 2021; 39:3613-3622.

Sonneveld P, von dem Borne P, Durian M, Hájek R, Boersma R, Wu K, Morelli A, Aquino S, Ludwig H, Bos G, Levin M, Benevolo G, Pascarella A, Troia R, Caravita di Toritto T, Zander T, Boccadoro M, Spencer A, Carvalho S, Palmas A, Cafro A, Mandigers C, Minnema M, van Marwijk Kooy M, Mellqvist U, Gimsing P, Waage A, Specchia G, Driessen C, Broijl A, Andersen N, Patriarca F, Palumbo G, Zamagni E, van der Velden V, Oliva S, Zweegman S, van der Holt B, Dozza L, Dimopoulos M, Petrucci M, Pantani L, Beksac M, Gay F, Montefusco V, Galli M, Liberati A, Zambello R, Vincelli I, Offidani M, Ballanti S, Croockewit A, Grasso M, Ypma P, Pour L, Belotti A, Hansson M, Gamberi B, Maisnar V, Cavo M. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. *Lancet Haematol* 2020; 7:e456-e468.

Engelhardt M, Straka C, Johnsen H, Waage A, Boegsted M, Lokhorst H, Hájek R, Morgan G, Boccadoro M, Ludwig H, Cavo M, Polliack A, Sonneveld P, Einsele H, Kropff M, Sezer O, Udi J, Kleber M, Spencer A, Rocci A, Knop S, Bruno B, Bringhen S, Pérez-Simón J, Zweegman S, Driessen C, Patriarca F, Gramatzki M, Terpos E, Palumbo A. European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. *Leuk Lymphoma* 2010; 51:2006-11.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch